Abstract
Chemotherapy-induced neuropathic pain (CINP) pain, such as oxaliplatin, has a very high prevalence (between 50 and 80% of cases) negatively impacting the quality of life of patients and may lead to treatment discontinuation. CINP preventive or symptomatic treatments are generally ineffective, making it necessary to investigate new therapeutic approaches to prevent or improve these symptom…